<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110355</url>
  </required_header>
  <id_info>
    <org_study_id>20120238</org_study_id>
    <nct_id>NCT02110355</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma</brief_title>
  <official_title>A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in
      combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a
      direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib
      combined with dabrafenib alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 3 parts: Part 1 - Dose Escalation, Part 2 - Dose Expansion and
      Part 3, a randomized Phase 2a.

      In both part 1 and 2, subjects will be enrolled open-label into 1 of 2 arms. For both Arm 1
      and Arm 2, the part 1 dose escalation is aimed at determining an AMG 232 maximum tolerated
      dose (MTD) with a fixed dose of the combination drug(s) and evaluating safety, tolerability,
      pharmacokinetics and pharmacodynamics of each combination. Part 2 dose expansion will enroll
      subjects to receive therapy with a dose and schedule of AMG 232 selected from the
      corresponding part 1 dose escalation. In part 2 subjects will be enrolled to confirm safety
      and tolerability and to assess clinical activity prior to proceeding to Part 3, Phase 2a. In
      Phase 2a, Subjects will be randomized open-label in a 1:1 ratio to receive AMG 232 in
      combination with trametinib plus dabrafenib versus trametinib plus dabrafenib alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2014</start_date>
  <completion_date type="Actual">December 27, 2018</completion_date>
  <primary_completion_date type="Actual">December 27, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of treatment-emergent adverse events, Results of safety laboratory tests, vital sign measurements, ECG measurements, PK parameters; Progression-free Survival Rate</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence and grade of treatment-emergent adverse events, including dose-limiting toxicities; AMG 232, trametinib, dabrafenib, and metabolite PK parameters; progression-free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to and duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, Progression-free and Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Objective Tumor Response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Oncology</condition>
  <condition>Oncology Patients</condition>
  <condition>Tumors</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 of Part 1 and 2 and Part 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 232 with Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 of Part 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 232</intervention_name>
    <description>Given as an oral tablet in escalating doses</description>
    <arm_group_label>AMG 232 with Trametinib</arm_group_label>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib is an anti-cancer agent</description>
    <arm_group_label>AMG 232 with Trametinib</arm_group_label>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib is an anti-cancer agent</description>
    <arm_group_label>AMG 232 with Trametinib and Dabrabenib</arm_group_label>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects must have histologically or cytologically confirmed metastatic
        cutaneous or mucosal melanoma, Able to swallow and retain orally administered medication,
        Adequate hematological, renal, hepatic, and coagulation laboratory assessments Exclusion
        Criteria: Clinically significant bleeding within 4 weeks of screening, Current use of
        warfarin, factor Xa inhibitors, and direct thrombin inhibitors, Infection requiring
        anti-infective treatments within 1 week of study enrollment, Anti-tumor therapy, Major
        surgery within 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <disposition_first_submitted>May 18, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 18, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 20, 2020</disposition_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

